vimarsana.com
  1. Home
  2. Live Updates
  3. Volunteer Trial - Breaking News

Latest Breaking News On - Volunteer trial - Page 1 : vimarsana.com

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing.

Michael hendersonDan budwickNoel kurdiCarl dambkowskiExchange commissionApogee therapeutics incApogee therapeuticsGlobenewswire incVolunteer trialChief executive officerChief medical officerFinancial conditionAnnual reportSafe harborPrivate securities litigation reform act

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.